February 7, 2019
Daiichi Sankyo said on February 6 that the US FDA has granted priority review for pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT), with a target action date set for August 3. Pexidartinib’s new...read more